Compare iShares Core S&P 500 ETF (IVV) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Natera Inc. Common Stock — how do they compare? iShares Core S&P 500 ETF trades at $770.94 (market cap $896.46B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: iShares Core S&P 500 ETF is far larger — about 15.7× Natera Inc. Common Stock's market cap, and iShares Core S&P 500 ETF is more actively traded (4,999,099 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Natera Inc. Common Stock for 0 Days on average.
| IVV | NTRA | |
|---|---|---|
Market Cap | $896.46B | $57.03B |
Volume | 4,999,099 | 1,131,157 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $425.64 |
52-Week Low | $634.93 | $179.42 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $781.42 with minimal daily movement. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. Recent news highlights mixed market sentiment with concerns about profit growth deceleration but optimism for year-end rallies. The ETF maintains its core position as a broad market exposure vehicle with consistent dividend distributions.
The outlook remains cautiously optimistic given the S&P 500's strong institutional support and historical performance. Key opportunities include potential year-end momentum and AI-driven growth in top holdings. Risks center on valuation concerns, profit growth slowdown projections, and market concentration in technology stocks that could amplify volatility during corrections.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
